https://www.selleckchem.com/pr....oducts/retatrutide.h
Treatments for metastatic breast cancer (MBC) improve survival but often impose prolonged symptom burden. We performed molecular characterization of 84 miRNAs in the circulating serum of women with MBC to explore possible early indicators of intervention response. Expression levels of miR-10a-5p and miR-211-5p were downregulated in nonresponders, but upregulated in responders (miR-10a-5p 0.40-fold and eightfold; miR 211-5p 0.47-fold and fourfold). miR-205-5p expression was upregulated in both nonresponders and responders, but to a g